Hydreight talks up August order growth

Executive Summary

• Hydreight Technologies reported record order growth for August 2025, processing over 80,000 orders, significantly surpassing internal forecasts of 55,000.
• The company reported 33% year-over-year revenue growth for H1 2025 and marked its third consecutive quarter of profitability, driven by disciplined cost control and operational efficiency.
• Strategic milestones include the closing of an $11.5 million oversubscribed convertible debenture financing, the acquisition of a 5% stake in Perfect Scripts LLC, and a binding LOI to acquire an AI-driven IV therapy support tool.

Key Details

• Order Volume & Growth:
  • August 2025 orders: >80,000 (vs. forecast of ~55,000).
  • January–August 2025 pharmacy order growth: ~86% year-over-year.
  • Nurse network growth (Jan–Aug 2025): Added 528 new licenses (up from 307 in 2024), a 72% YoY increase.
• Financial Performance:
  • H1 2025 Revenue Growth: 33% year-over-year.
  • Profitability: Third consecutive quarter of profitability.
  • Drivers: Strong pharmacy order growth, network expansion, disciplined cost control, and operational efficiency.
• Financing:
  • Closed an oversubscribed $11.5 million convertible debenture financing on Sept 4, 2025, including the full exercise of the overallotment option.
  • Use of proceeds: Growth capital for strategic initiatives, acquisition integration, and strengthening the balance sheet.
• M&A and Strategic Partnerships:
  • Perfect Scripts Stake: Signed definitive agreement on Sept 2, 2025, to acquire an initial 5% equity stake in Perfect Scripts LLC (a licensed 503A pharmacy), with an option to increase ownership up to 40%. Subject to exchange approval.
  • AI Acquisition: Entered into a binding letter of intent on Sept 8, 2025, to acquire Dynamic IV Therapy Support AI agent. Currently in due diligence. The AI tool is designed to guide providers with personalized IV treatment recommendations and serve as a marketing tool.
• Operational Updates:
  • VSDHOne Platform: Investment focused on making the platform fully modular to improve adoption rates and expand total addressable market.
  • Customer Lifetime Value (LTV): Focus on expanding patient care journeys from GLP-1 therapy to TRT, hair loss, ED medications, peptides, and at-home genetic/lab testing.
• Upcoming Events:
  • CEM Muskoka Capital Event: Sept 26–28, 2025.
  • Smallcap Discoveries Investor Event: Sept 29–30, 2025.
  • Planet Microcap Showcase: Oct 21–23, 2025.

Notable Quotes

• "Hydreight's performance in August was a clear signal of the growing strength of our platform... What excites us most is that this momentum is not driven by one product line, but by broad-based adoption across weight management, wellness and longevity care." — Shane Madden, CEO
• "We've been very deliberate in strengthening our foundation -- whether that's raising growth capital, expanding into pharmacy ownership or bringing AI-driven tools into our ecosystem. These steps are not about short-term wins, but about building a scalable, compliant and sustainable model that can grow with the needs of patients and providers alike." — Shane Madden, CEO